NASDAQ:ATHXAthersys Stock Price, Forecast & News

$2.78

-0.05 (-1.77 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$2.71

Now: $2.78▼

$2.91

50-Day Range

$2.07

MA: $2.73▼

$3.27

52-Week Range

$1.13

Now: $2.78▼

$4.38

Volume3.50 million shs

Average Volume3.54 million shs

Market Capitalization$546.21 million

P/E RatioN/A

Dividend YieldN/A

Beta-1.66

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke; and that is in Phase II clinical study for the treatment of patients with acute myocardial infarction, as well as that has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical need. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases. It also has license and collaboration agreements with RTI Surgical, Inc. to develop and commercialize biologic implants for orthopedic applications in the bone graft substitutes market; the University of Minnesota to develop MultiStem cell therapy platform; and Bristol-Myers Squibb Company to provide cell lines expressing well validated drug targets for compound screening and development. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Athersys has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $10.33, Athersys has a potential upside of 271.7% from its current price of $2.78.
Amount of Analyst Coverage
Athersys has only been the subject of 3 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Athersys has received 351 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Athersys has received 306 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Athersys has received 53.42% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Athersys and other stocks. Vote “Outperform” if you believe ATHX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATHX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Athersys does not currently pay a dividend.
Dividend Growth
Athersys does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Athersys insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $639,456.00 in company stock.
Percentage Held by Insiders
Only 15.31% of the stock of Athersys is held by insiders.
Percentage Held by Institutions
Only 17.29% of the stock of Athersys is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Athersys are expected to grow in the coming year, from ($0.30) to ($0.22) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Athersys is -9.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Athersys is -9.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Athersys has a P/B Ratio of 18.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.37 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ATHX

Previous Symbol

CUSIPN/A

CIK1368148

Webwww.athersys.com

Phone216-431-9900

Debt

Debt-to-Equity RatioN/A

Current Ratio2.36

Quick Ratio2.36

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$5.63 million

Price / Sales97.02

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.15 per share

Price / Book18.53

Profitability

EPS (Most Recent Fiscal Year)($0.29)

Net Income$-44,580,000.00

Net MarginsN/A

Return on Equity-184.41%

Return on Assets-104.23%

Miscellaneous

Employees75

Outstanding Shares196,480,000

Market Cap$546.21 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for ATHX and its competitors with MarketBeat's FREE daily newsletter.

Athersys (NASDAQ:ATHX) Frequently Asked Questions

How has Athersys' stock been impacted by COVID-19 (Coronavirus)?

Athersys' stock was trading at $1.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ATHX stock has increased by 117.2% and is now trading at $2.78. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Athersys?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Athersys.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Athersys.

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.02. View Athersys' earnings history.

What price target have analysts set for ATHX?

3 brokerages have issued 12-month price objectives for Athersys' stock. Their forecasts range from $5.00 to $14.00. On average, they anticipate Athersys' stock price to reach $10.33 in the next year. This suggests a possible upside of 271.7% from the stock's current price. View analysts' price targets for Athersys.

Has Athersys been receiving favorable news coverage?

News coverage about ATHX stock has trended somewhat positive this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Athersys earned a news impact score of 1.3 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutAthersys.

Who are some of Athersys' key competitors?

Some companies that are related to Athersys include Prestige Consumer Healthcare (PBH), Principia Biopharma (PRNB), Eidos Therapeutics (EIDX), Pacira Biosciences (PCRX), Ligand Pharmaceuticals (LGND), TG Therapeutics (TGTX), IGM Biosciences (IGMS), SAGE Therapeutics (SAGE), Heron Therapeutics (HRTX), Passage Bio (ZNTL), Madrigal Pharmaceuticals (MDGL), Epizyme (EPZM), Xencor (XNCR), Aurinia Pharmaceuticals (AUPH) and Theravance Biopharma (TBPH). View all competitors.

What other stocks do shareholders of Athersys own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Athersys investors own include Inovio Pharmaceuticals (INO), Novavax (NVAX), Trevena (TRVN), SLS International (SLS), Sorrento Therapeutics (SRNE), Helix Energy Solutions Group (HLX), Opko Health (OPK), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP) and Gilead Sciences (GILD).

Who are Athersys' key executives?

Athersys' management team includes the following people:

Dr. Gil Van Bokkelen, Co-Founder, Chairman & CEO (Age 58)
Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO & Sec. (Age 53)
Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 52)
Ms. Laura K. Campbell, Sr. VP of Fin. (Age 55)
Karen Hunady, Director of Corp. Communications & Investor Relations

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.93%), State Street Corp (1.44%), Geode Capital Management LLC (1.00%), Coastal Investment Advisors Inc. (0.43%), M&G Investment Management Ltd. (0.42%) and Nuveen Asset Management LLC (0.34%). Company insiders that own Athersys stock include John J Harrington, Laura K Campbell and William Lehmann Jr. View institutional ownership trends for Athersys.

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Morgan Stanley, UBS Group AG, WINTON GROUP Ltd, Deutsche Bank AG, Perkins Capital Management Inc., Legal & General Group Plc, and Raymond James & Associates. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr. View insider buying and selling activity for Athersys.

Which major investors are buying Athersys stock?

ATHX stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, State Street Corp, Geode Capital Management LLC, Coastal Investment Advisors Inc., Federated Hermes Inc., BlackRock Inc., Meeder Asset Management Inc., and Alliancebernstein L.P.. View insider buying and selling activity for Athersys.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $2.78.

How big of a company is Athersys?

Athersys has a market capitalization of $546.21 million and generates $5.63 million in revenue each year. The biopharmaceutical company earns $-44,580,000.00 in net income (profit) each year or ($0.29) on an earnings per share basis. Athersys employs 75 workers across the globe.

What is Athersys' official website?

The official website for Athersys is www.athersys.com.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]

This page was last updated on 6/7/2020 by MarketBeat.com Staff